The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.
Americans will soon be able to grab an over-the-counter treatment for heavy periods, cramps, headaches, and migraines; they’ll have prescription-free access to a drug for endometriosis and polycystic ovary syndrome; and they’ll be able to buy a medication that can mitigate the symptoms of menopause.
The U.S. Chamber of Commerce filed a motion Wednesday for a preliminary injunction to block the implementation of the Medicare Drug Price Negotiation program.